SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are serious
health problems worldwide. These two diseases have similar pathological spectra, ranging …

Aims SUSTAIN 10 compared the efficacy and safety of the anticipated most frequent
semaglutide dose (1.0 mg) with the current most frequently prescribed liraglutide dose in …

Recently non-alcoholic fatty liver disease (NAFLD) has grabbed considerable scientific
attention, owing to its rapid increase in prevalence worldwide and growing burden on end …

Over a relatively short period, obesity and type 2 diabetes have come to represent a large
medical and economic burden to global societies. The epidemic rise in the prevalence of …

ABSTRACT Glucagon-like peptide-1 (GLP-1) is a hormone of the incretin system
responsible for a variety of glucoregulatory effects, including glucose-dependent secretion of …

Insulin resistance (IR) is a metabolic state preceding development of type 2 diabetes (DM2),
cardiovascular disease, and neurodegenerative disorders, including Alzheimer's Disease …

Background: Liraglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1 RA)
based on the human GLP-1 sequence, with potential weight loss benefits, approved for the …

Background and aims Atherosclerosis in obesity and type 2 diabetes (T2DM) is associated
with low-grade inflammation (LGI) and dyslipidemia, where especially small, dense …

Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) and glucagon-like peptide-1
receptor agonists (GLP-1RAs) are two pharmacological classes that have proven their …